Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Killer cell lectin-like receptor subfamily F member 1 (KLRF1, also known as NKp80) is a transmembrane activating receptor expressed on nearly all human natural killer (NK) cells[2][6][8][9]. It is part of the C-type lectin-like receptor family and primarily functions in immunosurveillance by recognizing ligands (notably CLEC2B) expressed on myeloid cells, leading to NK cell activation, cytotoxicity, and cytokine secretion[2][8][9]. KLRF1 activation involves SRC and SYK kinases and participates in killing malignant cells as part of the innate immune response[2][8]. NKp80/KLRF1 has associative links in the literature with tumor immunology and hematologic malignancies such as acute myeloid leukemia; however, its direct therapeutic targeting is not yet a clinical reality[2].
Activation of NK cell-mediated cytotoxicity through ligand engagement (notably CLEC2B)[2][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Killer cell lectin-like receptor subfamily F member 1 (KLRF1).